Denali Therapeutics (DNLI) Other financing activities (2018)

Denali Therapeutics (DNLI) reported Other financing activities of $1.3 million for Q4 2018, up 2850.0% quarter-over-quarter from $44000.0 in Q1 2018.

Denali Therapeutics (DNLI) Other financing activities (2018) Analysis & Trends

Denali Therapeutics (DNLI) has 1 years of Other financing activities data on file, last reported at $1.3 million in Q4 2018.

Other financing activities for Q4 2018 came in at $1.3 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2019 was $1.3 million (up 2850.0% YoY), and the FY2025 annual result was $324000.0, changed N/A from the prior year.
Other financing activities grew to $1.3 million in Q4 2018 per DNLI's latest filing, from $44000.0 in the prior quarter.
Over five years, Other financing activities peaked at $1.3 million in Q4 2018 and troughed at $44000.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Denali Therapeutics	3.65 Bn	3.65 Bn	-

Download Data